The increasing accessibility of transcriptomic profiling has resulted in a surge of molecular pathway-based cancer subtyping in the last decade. Subtype-specific treatment and risk stratification have been demonstrated to improve survival rates and may allow for a more efficient allocation of resources. Pancreatic cancer (PaC), the third leading cause of cancer-related deaths in the United States, is known for its high intra- and inter-tumor heterogeneity. Pancreatic ductal adenocarcinoma (PDAC)